Pharmafile Logo
Pharmafocus logo
Advanced Search
pfizer_hq_new_york

Pfizer completes $15 billion Hospira acquisition

September 4, 2015
Biosimilar Drugs, Hospira, Pfizer, mergers and acquisitions

Pfizer has completed its acquisition of Illinois-based injectable drugs and infusion device specialist Hospira for around $15 billion.The deal, first announced …

News

Genentech Haemophilia therapy gets FDA breakthrough designation

September 4, 2015
Research and Development, Sales and Marketing Genentech, Roche, haemophilia a

Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …

News
NHS sign

Companies braced for new round of cancer cuts

September 4, 2015
Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, cuts

Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund …

News
Farydak

Novartis blood cancer drug Farydak receives EU approval

September 4, 2015
Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat

The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …

News
AstraZeneca plaque

AstraZeneca lung cancer drug clears UK market access hurdle

September 4, 2015
Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer

Follow @Pharmafocus

News
Entresto

Novartis heart failure drug available via EAMS

September 3, 2015
Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan

Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …

News
laptop stethoscope

Health ministers vow NHS tech revolution

September 3, 2015
Medical Communications Jeremy Hunt, NHS, data protection, digital technology, george freeman

UK health ministers have challenged the NHS to fully utilise technology, to empower patients to manage their own healthcare needs.Their …

News
cells

How ‘deep reading’ of the scientific literature will benefit pharma

September 3, 2015
Research and Development Big Data, Cancer, Data Mining, R&D, literature search, oncology

The US Defense Advanced Research Projects Agency (DARPA)’s $45 million ‘Big Mechanism’ initiative has an ambitious aim.It promises to “leapfrog …

Feature

NICE pushes biosimilars in rheumatoid arthritis guidance

September 3, 2015
Sales and Marketing

NICE has published final draft guidance confirming its recommended treatment options for rheumatoid arthritis.  For the first time copycat, or …

News
zarxio

Sandoz launches first US biosimilar

September 3, 2015
Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim

Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …

News
dun___bradstreet_4efa511357b57

Shire appoints Sara Mathew to board of directors

September 2, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Sara Mathew, Shire

Shire has appointed Sara Mathew to its board of directors as a non-executive director.Mathew will also be a member of …

Appointment
CEP report

Pharma ‘spends €40m to sway EU politicians’

September 2, 2015
Medical Communications EU, European Commission, TTIP, drug policy, lobbying, transparency

The pharma industry has excessive power over EU decision-makers and spends €40 million a year to influence EU drug policy, …

News
Alzheimer's brain

Amgen and Novartis partner on Alzheimer’s and migraine treatments

September 2, 2015
Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience

Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine.  The companies plan …

News
Novartis image

Two Novartis drugs get first in class EU approvals

September 2, 2015
Research and Development, Sales and Marketing Novartis

The European Commission has approved Revolade for severe aplastic anaemia, and the combination of Tafinlar and Mekinist for patients with …

News
Xarelto

Bayer backs safety of Xarelto after real-world data study

September 2, 2015
Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban

Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …

News
google logo

Sanofi joins Google in diabetes tech push

September 1, 2015
Medical Communications Andy Conrad, Google life sciences, Sanofi, Type 1 diabetes, diabetes, google, type 2 diabetes

Google is continuing its work in diabetes, by teaming up with pharma giants Sanofi to create new digital technologies and …

News
scales

Standardising the pharma benefit-risk assessment process

September 1, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, FDA, benefit-risk analysis, pharmacoepidemiology, pharmacovigilance

Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view …

Feature
Alexion sign

Alexion scores double EU approval

September 1, 2015
Manufacturing and Production, Sales and Marketing Alexion, EC, European Commission, Kanuma, Strensiq, asfotase alfa, sebelipase alfa, ultra rare disease, ultra-rare disease

Two treatments developed by ultra-rare disease specialists Alexion Pharmaceuticals are now approved for use in Europe. The European Commission approved …

News

Bristol-Myers Squibb makes big pharma deals

September 1, 2015
Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis

Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …

News
FDA sign

FDA issues gliptin joint pain warning

September 1, 2015
Manufacturing and Production DPP-4 inhibitors, ESC, FDA, TECOS, adverse effects, drug safety, gliptins, safety alert, safety warning

The FDA has issued a safety alert, warning of joint pain caused by the gliptins, a common class of drugs …

News
The Gateway to Local Adoption Series

Latest content

Campaign highlights low expectations among patients with depression

May 7, 2026

Practical AI toolkit launched to help manufacturers cut through complexity

May 6, 2026

Syngene appoints Maninder Kapoor Puri as CHRO

May 6, 2026

BioPhorum acquires PharmaX Solutions

May 5, 2026

Syngene appoints Abhijit Zutshi as CCO

May 5, 2026